Yunfeng K. Li

Kunming, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial.

Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2026

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: February 25, 2026

Dual immunosuppression mechanism induced by PTP1B in colorectal cancer: upregulation of PD-L1 by FOXO1/miR-34C/c-MYC axis and inhibition of the infiltration of CD8(+) T cell by downregulating of CXCL11.

Dual immunosuppression mechanism induced by PTP1B in colorectal cancer: upregulation of PD-L1 by FOXO1/miR-34C/c-MYC axis and inhibition of the infiltration of CD8(+) T cell by downregulating of CXCL11.

Journal: Journal of translational medicine

Published: January 20, 2026

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: December 10, 2025

Standardized surgical procedure of proximally extended resection and sphincter-preserving surgery (Tianhe Procedure) for rectal cancer after radiotherapy (2025 version).

Standardized surgical procedure of proximally extended resection and sphincter-preserving surgery (Tianhe Procedure) for rectal cancer after radiotherapy (2025 version).

Journal: Gastroenterology report

Published: December 06, 2025

Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Locally Advanced Rectal Cancer: A Multicenter Propensity Score-Matched Study.

Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Locally Advanced Rectal Cancer: A Multicenter Propensity Score-Matched Study.

Journal: Diseases of the colon and rectum

Published: October 30, 2025

Single-cell mapping of tumor-driven macrophage reprogramming via ETV4-MC1R underlies immunotherapy resistance in colorectal cancer.

Single-cell mapping of tumor-driven macrophage reprogramming via ETV4-MC1R underlies immunotherapy resistance in colorectal cancer.

Journal: International journal of surgery (London, England)

Published: August 22, 2025

C-Arg9-APCR3-VHL promotes β-catenin degradation via the VHL-mediated ubiquitin-proteasome system in APC-mutant colorectal cancer.

C-Arg9-APCR3-VHL promotes β-catenin degradation via the VHL-mediated ubiquitin-proteasome system in APC-mutant colorectal cancer.

Journal: International journal of biological macromolecules

Published: May 23, 2025

A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.

A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 07, 2025

Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre study.

Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre study.

Journal: BMC medicine

Published: December 28, 2024

ERO1α regulates colon cancer progression and 5-FU resistance through the miR-451a/ARF1 axis.

ERO1α regulates colon cancer progression and 5-FU resistance through the miR-451a/ARF1 axis.

Journal: International journal of colorectal disease

Published: November 08, 2024

CT measurement of blood perfusion in hepatocellular carcinoma: from basic principle, measurement methods to clinical application

CT measurement of blood perfusion in hepatocellular carcinoma: from basic principle, measurement methods to clinical application

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: October 16, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026